Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

mCRPC × 30 days × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 477 Neoplasms 415 Carcinoma, Non-Small-Cell Lung 366 Prostatic Neoplasms 315 Lung Neoplasms 242 Colorectal Neoplasms 233 Neoplasm Metastasis 194 Leukemia, Myeloid, Acute 183 Multiple Myeloma 180 Ovarian Neoplasms 164 Melanoma 162 Pancreatic Neoplasms 138 Squamous Cell Carcinoma of Head and Neck 112 Brain Neoplasms 112 Recurrence 108 Carcinoma, Hepatocellular 103 Endometrial Neoplasms 100 Lymphoma 99 Glioma 98 Glioblastoma 98 Uterine Cervical Neoplasms 97 Urinary Bladder Neoplasms 97 Triple Negative Breast Neoplasms 97 Stomach Neoplasms 95 Precursor Cell Lymphoblastic Leukemia-Lymphoma 94 Carcinoma, Renal Cell 94 Lymphoma, Non-Hodgkin 83 Hematologic Neoplasms 83 Leukemia, Lymphocytic, Chronic, B-Cell 80 Myelodysplastic Syndromes 78

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03395197 2026-03-12

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡